Company Profile: Acumetis

Life sciences companies are operating in a more complex commercial environment than ever before. Scientific innovation is moving quickly, regulatory expectations are rising, healthcare systems are under pressure, and companies must prove the value of their products earlier, more clearly and across more stakeholders.

For pharmaceutical and biotech companies, this creates a familiar challenge. The decisions that shape commercial success are rarely isolated. Early asset evaluation influences access strategy. Access evidence affects launch planning. Medical strategy shapes market confidence. Patient support can determine whether innovation reaches the people it is designed to help.

Yet, across the industry, these functions often remain fragmented. Different teams, agencies, and advisers may work on connected problems from separate vantage points. The result can be slower decision-making, diluted strategy, and missed opportunities, at the moments that matter most.

Acumetis has been created to address that challenge.

The company brings together five specialist life sciences consultancies - Herspiegel, Adivo Associates, Decisive Consulting, Fiecon and Sixsense Strategy Group - into a single integrated brand. Together, they form a global commercialisation partner designed to support better decision-making across the full biopharma product lifecycle.

Acumetis is built around a simple premise: life sciences companies need sharper judgement and more connected support as they take products from development through to launch and in-market performance.

Its model brings commercial, insights, medical, market access, and patient strategy together under one roof. Rather than treating these disciplines as separate workstreams, Acumetis connects them around the critical decisions that shape product value.

That matters because commercialisation now starts long before launch. Companies need to understand market opportunity, payer expectations, clinical differentiation, patient need, and competitive dynamics at earlier stages of development. They also need to keep those insights connected as an asset moves through evidence generation, access planning, launch execution, and performance optimisation.

Acumetis is designed to provide that continuity. Its teams support clients across the asset lifecycle, from evaluation and market access strategy through to launch excellence and in-market growth.

The launch of Acumetis reflects a wider shift in life sciences advisory. Companies increasingly need partners that can combine specialist depth with global reach.

The five businesses that now form Acumetis bring established expertise across commercial strategy, value and access, patient support, insights, analytics, and medical affairs. Collectively, they have supported more than 200 product launches and worked with more than 150 life sciences organisations, including many of the world’s leading pharmaceutical companies.

The combined company has more than 350 experts globally, with operational experience across more than 50 geographic markets. This gives Acumetis both the scale to support international programmes and the specialist knowledge needed to navigate local market realities.

For clients, that combination is important. Commercialisation is not simply a question of having the right strategy. It requires understanding how evidence, access, customer engagement, medical affairs, and patient support work together across different markets and stakeholder groups.

Acumetis’ model is intended to help clients see those connections more clearly, then act on them with greater confidence.

One of the pressures facing life sciences companies is the need to make high-stakes decisions faster. Timelines are compressed. Competition is intense. Evidence requirements are more demanding. The cost of getting decisions wrong can be significant.

Acumetis positions itself as a partner for those decision points. Its work is grounded in rigorous analysis, practical judgement, and measurable outcomes. The name reflects that founding idea: “acumen”, meaning the ability to make sound judgements, and “Metis”, the Greek concept of practical wisdom.

That combination matters in an industry where data alone is not enough. Companies need to know what the evidence means, which decisions it should inform, and how to turn insight into action.

Acumetis brings together data, capability, and strategic counsel to help clients reframe complex problems and shape solutions that are both imaginative and achievable.

Launch remains one of the most important moments in a product’s lifecycle, but the work that determines launch success often begins much earlier.

A strong launch requires alignment across clinical, commercial, medical, market access, and patient functions. It requires clear evidence of value, a strong understanding of stakeholder needs, and the ability to adapt as market conditions change.

Acumetis has been formed with this end-to-end perspective in mind. Its integrated model is intended to help clients move from strategy to execution without losing momentum or clarity.

The company’s experience across more than 200 launches gives it a practical understanding of where strategies can succeed, where they can stall, and what needs to happen to turn scientific innovation into commercial and patient impact.

The launch of Acumetis comes at a time when the life sciences industry is looking for more connected ways to work.

As companies face rising complexity, the old model of separate advisory inputs is under pressure. Clients need partners that can bring together deep expertise, integrated thinking, and practical delivery across the full product lifecycle.

Acumetis has been purpose-built for that environment. By combining five established consultancies into one global brand, it aims to help life sciences companies make better decisions, unlock value, and deliver stronger outcomes for patients.

For an industry where the path from innovation to impact is rarely straightforward, Acumetis offers a clear proposition: connected expertise, practical wisdom, and commercialisation support designed around the moments that matter most.

Acumetis is a global expert commercialisation partner purposefully built to help life sciences companies win in the age of connectivity. With an integrated model spanning the full asset lifecycle, deep functional and therapeutic-area expertise, and rigorous, outcome-driven thinking, Acumetis reframes complex problems and shapes solutions that are both imaginative and achievable.

With more than 350 experts globally and experience across 50+ geographic markets, Acumetis helps clients unlock value, accelerate performance and deliver better outcomes for patients.